Monopar Therapeutics (MNPR) News Today $16.93 -15.73 (-48.16%) (As of 10/25/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period Monopar Therapeutics (NASDAQ:MNPR) Shares Gap Down - Time to Sell?Monopar Therapeutics (NASDAQ:MNPR) Shares Gap Down - Time to Sell?October 25 at 2:05 PM | marketbeat.comMonopar Therapeutics Skyrockets 400% on Licensing DealMonopar Therapeutics (NASDAQ: MNPR) surged over 400% on Thursday after securing a licensing deal with AstraZeneca for a once-terminated Phase 3 drug.October 25 at 8:12 AM | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Sets New 52-Week High - Should You Buy?Monopar Therapeutics (NASDAQ:MNPR) Reaches New 1-Year High - Here's WhyOctober 24 at 4:14 PM | marketbeat.comMonopar Shares Rise on AstraZeneca Licensing DealOctober 24 at 1:06 PM | marketwatch.comMonopar Shares Surge on AstraZeneca Licensing Deal -- UpdateOctober 24 at 1:06 PM | marketwatch.comMonopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug CandidateOctober 24 at 8:04 AM | markets.businessinsider.comMonopar Therapeutics Presents Human Clinical Dosimetry Data at European Association of Nuclear Medicine October 24 at 2:05 AM | americanbankingnews.comMonopar Therapeutics Unveils Promising Radiopharmaceutical DataOctober 22 at 8:54 PM | markets.businessinsider.comMonopar Therapeutics presents data from radiopharma program based on MNPR-101October 22 at 8:54 PM | markets.businessinsider.comMonopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024October 22 at 8:00 AM | globenewswire.comMonopar Therapeutics Expands Portfolio with New Patent FilingOctober 16, 2024 | finance.yahoo.comMonopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and LinkersOctober 15, 2024 | globenewswire.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Sees Large Decrease in Short InterestMonopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) was the recipient of a significant drop in short interest in September. As of September 30th, there was short interest totalling 112,400 shares, a drop of 82.8% from the September 15th total of 652,500 shares. Approximately 6.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 806,900 shares, the short-interest ratio is presently 0.1 days.October 10, 2024 | marketbeat.comMonopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer TrialOctober 8, 2024 | finance.yahoo.comMonopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced CancersOctober 7, 2024 | markets.businessinsider.comMonopar Therapeutics (NASDAQ:MNPR) Stock, Short Interest ReportOctober 2, 2024 | benzinga.comMonopar Therapeutics (NASDAQ:MNPR) Stock, Insider Trading ActivityOctober 1, 2024 | benzinga.comMONOPAR THERAP. NEW (1IY0.MU)September 12, 2024 | ca.finance.yahoo.comMonopar Shares Rise After Clinical Data on Cancer TreatmentSeptember 12, 2024 | marketwatch.comMonopar Therapeutics Inc.: Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-ZrSeptember 12, 2024 | finanznachrichten.deMonopar Therapeutics Soars Over Announcement Of Positive Data From MNPR-101-Zr Phase 1 TrialSeptember 12, 2024 | markets.businessinsider.comWhy Monopar Therapeutics (MNPR) Stock Is Skyrocketing TodaySeptember 12, 2024 | msn.comMonopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-ZrSeptember 12, 2024 | globenewswire.comMonopar to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | finance.yahoo.comMonopar Regains Compliance with Nasdaq Minimum Bid Price RuleAugust 27, 2024 | globenewswire.comMonopar Therapeutics Inc.: Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced CancersAugust 21, 2024 | finanznachrichten.deMonopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced CancersAugust 21, 2024 | globenewswire.comBuy Rating Affirmed for Monopar Therapeutics on Clinical Progress and Strategic Financial PositioningAugust 16, 2024 | markets.businessinsider.comMonopar Therapeutics Inc. (1IY0.F)August 15, 2024 | au.finance.yahoo.comMonopar Therapeutics Inc.: Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-ZrAugust 14, 2024 | finanznachrichten.deMonopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-ZrAugust 14, 2024 | globenewswire.com1IY.SG,0P0001LR0T,0 (1IY.SG)August 13, 2024 | uk.finance.yahoo.comMonopar Therapeutics Inc.: Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent DevelopmentsAugust 9, 2024 | finanznachrichten.deMonopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent DevelopmentsAugust 9, 2024 | finance.yahoo.comMonopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent DevelopmentsAugust 9, 2024 | globenewswire.comMonopar Therapeutics Announces 1-for-5 Reverse Stock SplitAugust 9, 2024 | globenewswire.comMonopar Therapeutics Inc MNPRAugust 3, 2024 | morningstar.comMonopar Therapeutics Inc: Positioned for Growth with Strategic Radiopharmaceutical Pivot and Promising Preclinical DataJuly 24, 2024 | markets.businessinsider.comMonopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24June 25, 2024 | globenewswire.comMonopar Therapeutics Inc. (NASDAQ:MNPR) COO Buys $15,175.92 in StockJune 25, 2024 | insidertrades.comInsider Buying: Monopar Therapeutics Inc. (NASDAQ:MNPR) COO Buys 12,000 Shares of StockJune 18, 2024 | insidertrades.comMonopar and NorthStar Amend & Extend CollaborationJune 11, 2024 | globenewswire.comMonopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual MeetingJune 10, 2024 | globenewswire.comPenny Stocks That Insiders Are Loading Up On: 3 Names to Watch CloselyJune 5, 2024 | investorplace.comMonopar Therapeutics Inc.: Monopar Announces CFO SuccessionMay 24, 2024 | finanznachrichten.deMonopar Therapeutics: CFO Kim Tsuchimoto To Retire - Quick FactsMay 24, 2024 | markets.businessinsider.comMonopar Announces CFO SuccessionMay 24, 2024 | globenewswire.comBuy Rating Affirmed for Monopar Therapeutics on Strategic Shift and Pipeline PotentialMay 10, 2024 | markets.businessinsider.comMNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q1 2024May 9, 2024 | investorplace.comMonopar Therapeutics Inc.: Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma PipelineMay 9, 2024 | finanznachrichten.de Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Newton is finally here! (Ad)After Roger, one of the first guys I worked with behind the scenes here is Graham. I’ve been really impressed by some of what he’s come up with! But his brand new Newton indicator might take the cake. It’s one of the easiest “buy/sell” tools I’ve ever seen. Just buy when it lights up green, and sell when it goes red. Graham recently identified three NEW potential breakout stocks using Newton, and he’s sharing them in a FREE video. Just sign up here to learn more - we are having a live demo on Monday MNPR Media Mentions By Week MNPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNPR News Sentiment▼0.530.75▲Average Medical News Sentiment MNPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNPR Articles This Week▼121▲MNPR Articles Average Week Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Vistagen Therapeutics News Citius Pharmaceuticals News Daré Bioscience News Edesa Biotech News Merrimack Pharmaceuticals News G1 Therapeutics News Cryoport News Fate Therapeutics News Lexeo Therapeutics News Zevra Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNPR) was last updated on 10/25/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored“Hear That Whoosh Sound? It’s the Great Power Suck of 2025”We’re coming to the end of the line for the traditional energy grid. Look what’s happening in California.Traders Agency | SponsoredInvest in the company that won over the DragonsThe pioneer in smart-doorbell technology, RING, pitched their business on the hit show Shark Tank at a valuati...RYSE | SponsoredPutin proposes new currencyRussian leader Vladimir Putin just unveiled the first physical mockup of a proposed new currency. Many spec...Stansberry Research | SponsoredONE crypto stock +526% in under 60 daysCryptos are screaming higher right now. Yet, this ONE started a shooting up a little under 60 days ago.The Bitcoin Capitalist | SponsoredHe called Nvidia at 80 cents.1 Here’s his next AI pick …America is running out of power … Vast sections of the United States — and the world — are facing an impend...Weiss Ratings | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Monopar Therapeutics Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
